This Article Full Text Full Text (PDF) Online Supplement All Versions of this Article: 200411-1549OCv1 172/7/848    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Martorana, P. A. Articles by Lungarella, G. Search for Related Content PubMed PubMed Citation Articles by Martorana, P. A. Articles by Lungarella, G.

Roflumilast Fully Prevents Emphysema in Mice Chronically Exposed to Cigarette Smoke

Department of Physiopathology and Experimental Medicine, University of Siena, Siena, Italy; and ALTANA Pharma, Konstanz, Germany

Correspondence and requests for reprints should be addressed to Prof. Piero A. Martorana, D.V.M., Department of Physiopathology and Experimental Medicine, University of Siena, Via Aldo Moro 6, I-53100 Siena, Italy. E-mail: martorana{at}unisi.it

Rationale: There is a need for new agents capable of suppressing the inflammatory response in chronic obstructive pulmonary disease. Objectives: This study evaluated the effects of roflumilast, a phosphodiesterase 4 (PDE4) inhibitor on acute lung inflammation and chronic lung changes in models of cigarette exposure in mice.

Methods: Roflumilast was given orally either at 1 mg/kg (R1) or at 5 mg/kg (R5). In the acute model (five cigarettes for 20 minutes), bronchoalveolar lavage fluid (BALF) changes were investigated at 4 and 24 hours. In the chronic model (three cigarettes/day for 7 months), morphometric and biochemical parameters were assessed at 7 months.

Measurements and Main Results: Acute exposure caused a fivefold increase in BALF neutrophils. Both doses of roflumilast partially prevented (by 30%) this increase. In addition, after smoke exposure, R1 increased BALF interleukin-10 by 79% and R5 by 129%. Chronic smoke exposure caused a 1.8-fold increase in lung macrophage density, emphysema, an increase of the mean linear intercept (+21%), a decrease of the internal surface area (–13%), and a drop (–13%) in lung desmosine content. R1 did not have any effect, whereas R5 prevented the increase in lung macrophage density by 70% and fully prevented the other changes. In addition, in the smoke-exposure group, 63% of the mice showed goblet cell metaplasia, and neither of the doses of roflumilast had any effect.

Conclusions: This study shows for the first time that a PDE4 inhibitor partially ameliorates lung inflammation and fully prevents parenchymal destruction induced by cigarette smoke.

Key Words: chronic obstructive pulmonary disease • interleukin-10 • lung inflammation

This article has been cited by other articles:

				P. J. Barnes and B. R. Celli Systemic manifestations and comorbidities of COPD Eur. Respir. J., May 1, 2009; 33(5): 1165 - 1185. [Abstract] [Full Text] [PDF]

				P. J. Barnes Future Treatments for Chronic Obstructive Pulmonary Disease and Its Comorbidities Proceedings of the ATS, December 1, 2008; 5(8): 857 - 864. [Abstract] [Full Text] [PDF]

				P. J. Barnes Emerging Pharmacotherapies for COPD Chest, December 1, 2008; 134(6): 1278 - 1286. [Abstract] [Full Text] [PDF]

				A. Churg, M. Cosio, and J. L. Wright Mechanisms of cigarette smoke-induced COPD: insights from animal models Am J Physiol Lung Cell Mol Physiol, April 1, 2008; 294(4): L612 - L631. [Abstract] [Full Text] [PDF]

				S. Medicherla, M. F. Fitzgerald, D. Spicer, P. Woodman, J. Y. Ma, A. M. Kapoun, S. Chakravarty, S. Dugar, A. A. Protter, and L. S. Higgins p38{alpha}-Selective Mitogen-Activated Protein Kinase Inhibitor SD-282 Reduces Inflammation in a Subchronic Model of Tobacco Smoke-Induced Airway Inflammation J. Pharmacol. Exp. Ther., March 1, 2008; 324(3): 921 - 929. [Abstract] [Full Text] [PDF]

				H. Mori, T. Nose, K. Ishitani, S. Kasagi, S. Souma, T. Akiyoshi, Y. Kodama, T. Mori, M. Kondo, S. Sasaki, et al. Phosphodiesterase 4 inhibitor GPD-1116 markedly attenuates the development of cigarette smoke-induced emphysema in senescence-accelerated mice P1 strain Am J Physiol Lung Cell Mol Physiol, February 1, 2008; 294(2): L196 - L204. [Abstract] [Full Text] [PDF]

				R. A. McIvor Future options for disease intervention: important advances in phosphodiesterase 4 inhibitors Eur. Respir. Rev., September 1, 2007; 16(105): 105 - 112. [Abstract] [Full Text] [PDF]

				R. Hermann, W. Siegmund, T. Giessmann, K. Westphal, A. Weinbrenner, B. Hauns, F. Reutter, G. Lahu, K. Zech, and T. D. Bethke The Oral, Once-Daily Phosphodiesterase 4 Inhibitor Roflumilast Lacks Relevant Pharmacokinetic Interactions With Inhaled Budesonide J. Clin. Pharmacol., August 1, 2007; 47(8): 1005 - 1013. [Abstract] [Full Text] [PDF]

				A. Churg, R. Wang, X. Wang, P.-O. Onnervik, K. Thim, and J. L Wright Effect of an MMP-9/MMP-12 inhibitor on smoke-induced emphysema and airway remodelling in guinea pigs Thorax, August 1, 2007; 62(8): 706 - 713. [Abstract] [Full Text] [PDF]

				B. R. Celli and P. J. Barnes Exacerbations of chronic obstructive pulmonary disease Eur. Respir. J., June 1, 2007; 29(6): 1224 - 1238. [Abstract] [Full Text] [PDF]

				S. M. Janciauskiene, I. M. Nita, and T. Stevens {alpha}1-Antitrypsin, Old Dog, New Tricks: {alpha}1-ANTITRYPSIN EXERTS IN VITRO ANTI-INFLAMMATORY ACTIVITY IN HUMAN MONOCYTES BY ELEVATING cAMP J. Biol. Chem., March 23, 2007; 282(12): 8573 - 8582. [Abstract] [Full Text] [PDF]

				J. L. Wright and A. Churg Current Concepts in Mechanisms of Emphysema Toxicol Pathol, January 1, 2007; 35(1): 111 - 115. [Abstract] [Full Text] [PDF]

				T. D. Bethke, G. M. Bohmer, R. Hermann, B. Hauns, R. Fux, K. Morike, M. David, D. Knoerzer, W. Wurst, and C. H. Gleiter Dose-Proportional Intraindividual Single- and Repeated-Dose Pharmacokinetics of Roflumilast, an Oral, Once-Daily Phosphodiesterase 4 Inhibitor J. Clin. Pharmacol., January 1, 2007; 47(1): 26 - 36. [Abstract] [Full Text] [PDF]

				B. Hauns, R. Hermann, A. Hunnemeyer, R. Herzog, D. Hauschke, K. Zech, and T. D. Bethke Investigation of a potential food effect on the pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, in healthy subjects. J. Clin. Pharmacol., October 1, 2006; 46(10): 1146 - 1153. [Abstract] [Full Text] [PDF]

				T. H. March, J. A. Wilder, D. C. Esparza, P. Y. Cossey, L. F. Blair, L. K. Herrera, J. D. McDonald, M. J. Campen, J. L. Mauderly, and J. Seagrave Modulators of Cigarette Smoke-Induced Pulmonary Emphysema in A/J Mice Toxicol. Sci., August 1, 2006; 92(2): 545 - 559. [Abstract] [Full Text] [PDF]

				L. M. Fabbri, F. Luppi, B. Beghe, and K. F. Rabe Update in chronic obstructive pulmonary disease 2005. Am. J. Respir. Crit. Care Med., May 15, 2006; 173(10): 1056 - 1065. [Full Text] [PDF]

				H. Parameswaran, A. Majumdar, S. Ito, A. M. Alencar, and B. Suki Quantitative characterization of airspace enlargement in emphysema J Appl Physiol, January 1, 2006; 100(1): 186 - 193. [Abstract] [Full Text] [PDF]